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Objective: This paper describes the rationale andmethodology of the PROSPECTS study, a studywhich aims to as-
sess the course and prognosis of medically unexplained physical symptoms (MUPS), in terms of symptom sever-
ity and physical and social functioning. Additionally, it aims to identify different course types and to determine
which factors are associated with these course types. Based on these factors, one or more prediction models
will be developed.
Methods: This study is a prospective, multicenter longitudinal cohort studywith 1 baseline and 4 follow-upmea-
surements during a 3 year period. 450MUPS patients (age 18–70 years) will be included, divided over a primary
care group, recruited in general practices, and a secondary/tertiary care group, recruited in specializedMUPS care
programs.
Main study parameters/endpoints: Primary outcomemeasures are severity of symptoms and degree of functional
impairment. Secondary outcome measures are health care consumption and level of depressive symptoms and
anxiety. Potential predictors are based on current theoretical models describing the perpetuation of MUPS and
include somatic, psychological and social factors.
Latent Class Growth Mixture Modeling will be used to identify distinct course types. Logistic regression analysis
will be used to identify risk factors associated with these course types. Finally, one or more multivariate predic-
tion models for the course of MUPS will be developed and tested.
Conclusion: The PROSPECTS study aims to enhance our insight into the course of MUPS, thus contributing to
better recognition of future patients at risk for persistent MUPS.© 2014 Elsevier Inc. All rights reserved.Background
In all health care settings patients present with physical symptoms,
such as fatigue, dizziness and pain, for which no sufﬁcient somatic ex-
planation is found after proper medical examination. Such symptoms
are called medically unexplained physical symptoms (MUPS). MUPS
are very common, especially in primary care. Around 25–50% of the
complaints that patients present to their general practitioner (GP) re-
main unexplained [1]. Fortunately, almost 80% of these episodes remain
restricted to one doctor–patient contact [2], indicating that most MUPStice and Elderly Care Medicine,
700, 1100 SN Amsterdam, The
obile); fax: +31 20 4448361.
ghts reserved.may be self-limiting. However, around 20–30% of patients develop
persisting symptoms, which can be severe and disabling [3,4].
Due to the variation in presentation and duration, MUPS can be
regarded as a continuum ranging from mild (and often self-limiting)
symptoms, to chronic severe symptoms, which are also seen in func-
tional somatic syndromes such as Irritable Bowel Syndrome and Chron-
ic Fatigue Syndrome. At the severe end of the continuum, symptoms are
oftenmore numerous and psychiatric co-morbidity often occurs [5]. The
diversity in the nature and severity of symptoms creates challenges in
deﬁning and describing the various forms of MUPS [6]. In this study
we choose to use the term ‘MUPS’ as a general description of the entire
spectrum of physical symptoms, which last at least several weeks, and
for which no sufﬁcient explanation can be found after proper medical
examination. This is in linewith the recently published Dutch ‘Multidis-
ciplinary Guideline forMUPS and SomatoformDisorders’ [5] and gives a
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(physical or psychological) causal explanation.
Costs and societal relevance of MUPS
Patients with persistent MUPS have great risk of functional impair-
ment and experience high levels of psychological distress [7–9]. Addi-
tionally, persistent MUPS are associated with high costs [10]. It is
known that MUPS patients are often exposed to unnecessary diagnostic
procedures and may use superﬂuous medication [11–13]. Outpatient
and inpatient medical care utilization is approximately twice as high
in patients suffering from severe MUPS, when compared to patients
without MUPS [14]. Total costs for this patient group are even higher,
due to work- and insurance related costs [15]. In the Netherlands, it is
estimated that 30% of long term absence of work is caused by MUPS
[16].
Mechanisms contributing to MUPS
Several theories are available for the mechanisms that play a role in
the development and persistence of MUPS. The cognitive behavioral
model is seen as a meta-model, incorporating many of these theories
[17,18]. It provides explanations for physical symptoms in different do-
mains, including somatic causes, illness perceptions, illness behavior
and illness predispositions.
One of the theories incorporated in the model is the somatosensory
ampliﬁcation theory, which suggests that a physical sensation leads to
increased attention to this sensation, which in turn leads to (faulty)
attributions and cognitions about it. This creates a vicious circle, as it
ampliﬁes the symptom perception [19].
A second theory incorporated in the model is the sensitivity theory.
This theory suggests that some individuals are more vulnerable for de-
veloping or maintaining physical symptoms than others. Factors that
have been found to be related to this vulnerability are personality traits,
such as neuroticism, catastrophic thinking and traumatic experiences in
early childhood [17].
A third theory is based on the fact that stress (physical or psycholog-
ical) inﬂuences the bodily hormonal stress system: the hypothalamic
pituitary adrenal axis (HPA axis). Prolonged stress may lead to HPA
axis down regulation and reduced cortisol production. As a result stress
sensitivity increases [20]. This theory reﬂects the interplay between
body and mind and may therefore provide a concrete link between
psychological burden and physical symptoms.
A narrative review showed some evidence for the inﬂuence of these
and other theoretical elements on MUPS [18]. However, it is unknown
which elements play the most important role in the persistence of
MUPS. Better insight in these contributing factors might provide clues
for treatment of MUPS.
Prognosis and treatment of MUPS
Little is known about the course of MUPS. In a recent review, Olde
Hartman et al. summarized cohort studies about the course and progno-
sis of MUPS [21]. They found that very few, highly heterogenic, studies
have been performed. Additionally, included studies had methodologi-
cal ﬂaws. Baseline duration of symptoms was often unknown, possible
treatments were not described and duration of follow-upwas generally
short (6 to 15 months). They concluded that although 50% of patients
improve or recover completely, the symptoms of 10–30% of patients
with MUPS deteriorate or become chronic. Due to the heterogeneity in
the studies, they could not identify prognostic factors for the course of
MUPS. Due to the short follow-up, no conclusions could be drawn
about the stability of the short term outcomes (e.g. the long term symp-
tom recurrence rate after an initial recovery is currently unknown).
Interventions used to treat persistentMUPS have shown disappoint-
ingly little effect. For cognitive behavioral therapy (CBT) empiricalsupport has been found in some studies, but effect sizes were small. A
possible explanation could be the lack of focus on a well deﬁned target
population. Identiﬁcation of prognostic subgroupswouldmake it possi-
ble to offer CBT to those patients who actually need and may beneﬁt
from it. Additionally, it is unclear which components of CBT are effec-
tive. This may be caused by the lack of knowledge about factors playing
the most important role in inﬂuencing the course of MUPS [22–24].
Based on current knowledge, we can say that MUPS is mostly self-
limiting, butwhenMUPS persist, they have a great personal and societal
impact. We know very little about the long-term course of MUPS. It is
unclear which percentage of patients develops persistent MUPS in
different health care settings andwhich factors contribute to the persis-
tence of MUPS. Given these gaps in current knowledge, the PROSPECTS
study has 3 main study objectives:
Aims of this study
1. To assess the long-term course of MUPS presented in different set-
tings (primary care and secondary/tertiary care) in terms of severity
of symptoms and functional impairment.
2. To identify different course types, based on the course of symptom
severity and functional impairment.
3. To determine which baseline characteristics are associated with fa-
vorable and unfavorable course types and to develop a multivariate
prediction model for the course of MUPS.
Methods
Study design
This is a prospective cohort study of patients with MUPS in multiple
health care settings. The duration of follow-up will be 3 years. After
baseline measurement, follow-up measurements will take place after
6, 12, 24 and 36 months. Information will be collected through
questionnaires and saliva samples. The Medical Ethics Committee of
the VU University Medical Center approved the study protocol
(May 10th 2013). Written informed consent will be obtained from all
study participants.
Health care settings
In primary care, the study will be carried out in general practices
linked to the VU University Medical Center. These practices are located
in urban aswell as rural areas across theNetherlands. Approximately 50
general practitioners will be included, who have experience with the
electronic ICPC (International Classiﬁcation of Primary Care) coding
system [25]. The structure of the ICPC coding system is, though less
detailed, comparable with the ICD classiﬁcation (the International
Classiﬁcation of Diseases) [26].
In secondary and tertiary care the studywill be conducted in organi-
zations, which are participating in an integrated care program forMUPS
patients in greater Amsterdam. These are the psychiatric department of
the VU University Medical Center (VUmc); GGZ Ingeest, a secondary
mental health care organization; and Reade, a center for rehabilitation
medicine.
Patients
Inclusion criteria
The study population will consist of patients between 18and
70 years old, suffering from MUPS. We deﬁne MUPS as the presence
of physical symptoms, which have lasted at least several weeks and
for which no sufﬁcient explanation has been found after propermedical
examination by a physician. Additionally, the patient has to have a score
of 2 for at least one symptom of the PHQ-15 questionnaire (indicating
that the symptom is bothering a lot).
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about physical symptoms. In the original validation study, cut offs of 5
and 10 were suggested, based on the correlation of these scores with
the presence of a somatoform disorder according to the PRIME-MD
diagnostic interview for common mental disorders [29]. However, as
our deﬁnition of MUPS only requires the existence of at least one both-
ering symptom as a criterion, a lower cut off score of 2 for at least one
symptom will be used in this study. By using this threshold, we aim to
select a population which reﬂects the entire spectrum of MUPS, cover-
ing patients with mild symptoms, as well as patients with severe
symptoms.
Exclusion criteria
− A sufﬁcient medical explanation for the symptoms, according to the
physician.
− Incomplete diagnostic evaluation of the symptoms, according to the
physician.
− Insufﬁcient command of the Dutch language.
− A cognitive or visual impairment that prohibits participating in a
questionnaire survey.
− Severe psychopathology (e.g. psychotic disorder, bipolar disorder).
− Pregnancy.
− Cancer diagnosed in 5 years prior to inclusion.
− Another life threatening condition or a short life expectancy.
Inclusion procedure
A ﬂowchart of the inclusion methods, both in primary and in
secondary/tertiary care, is given in Fig. 1.Fig. 1. Flowchart inclusion prIn primary care, patients at risk for MUPS will be searched, using an
electronic database search, based on a list of 23 unexplained physical
complaints composed by Robbins et al. [30]. The symptoms on this list
are associated with functional somatic syndromes such as Chronic
Fatigue Syndrome or Irritable Bowel Syndrome. Symptoms are likely
to be unexplained when they are on the ‘Robbins list’ and a matching
diagnosis ICPC code (meaning an ICPC code N70) is lacking.
Patients who visited their general practitioner (GP) twice ormore in
the last 3months with one or more of these symptoms (without a
matching ICPC diagnosis code N70 in the patient's electronic ﬁle) will
be selected. We use 2 visits as a cut off, as the presentations of symp-
toms which are limited to one doctor–patient contact are not the sub-
ject of this study. However, as MUPS patients can suffer from multiple
symptoms, symptoms presented in these 2 visits are allowed to be
different.
Selected patients are checked for exclusion criteria by their own GP.
The ﬁrst 2 exclusion criteria (a sufﬁcient medical explanation for the
symptoms and incompleteness of diagnostic evaluation) are based on
the criteria for MUPS as described in the Background section. Patients
without exclusion criteria receive the PHQ-15 questionnaire by mail.
Patients who return the questionnaire and have a score of 2 for at
least one symptom are eligible and will be approached for informed
consent and inclusion.
In secondary and tertiary care, all newly referred patients with
MUPS as the reason for referral are screened for in- and exclusion
criteria by the physician performing the intake consultation. The
same criteria as in primary care are used. Selected patients receive the
PHQ-15 by mail. Patients who return the questionnaire and have score
of 2 for at least one symptom are eligible and will be approached for
informed consent.ocess PROSPECTS study.
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Patient characteristics
We will mail questionnaires at baseline to assess general character-
istics (i.e. gender, age, length, weight, country of origin, education level,
occupation) and medical characteristics (medical history, chronic med-
ical conditions and life style parameters). Additionally, amore extensive
overview of number and severity of physical symptoms will be created
using the PSQ questionnaire, an extensive Dutch questionnaire on 51
physical symptoms [63].
Primary and secondary outcomes
All questionnaires used to assess the outcomes were selected based
on their validity, previous use in this speciﬁc population, availability of
reference values and questionnaire length.
Severity of symptoms and functional impairment at follow-up are
the primary outcomes, measured respectively with the Patient Health
Questionnaire-15 [27,28] and the RAND 36-item health survey ques-
tionnaire [31]. Secondary outcomes are health care use (Trimbos/
iMTA questionnaire for Costs associated with Psychiatric Illness [32])
and level of depressive symptoms and anxiety (Quick Inventory of De-
pressive Symptomatology [33] and Beck Anxiety Inventory [34,35]
questionnaires). These outcomes will be measured at baseline and at
all follow-up moments.
Potential predictors
The choice of potential predictors of the course ofMUPS is based on a
number of theories incorporated in the cognitive behavioral model.
Therefore, the theories mentioned in the Introduction and most other
theories in the meta-model will be reﬂected.
Based on the somatosensory ampliﬁcation theory the concepts of
hypervigilance (SomatoSensory Ampliﬁcation Scale [36,37]), illness
cognitions, causal attributions and coping (Cognitive and Behavioural
Responses to symptoms Questionnaire [38]) and illness perception
(Illness Perception Questionnaire [39,40]) were selected.Table 1
Used questionnaires and time points for administration
Instrument
General characteristics:
Patient characteristics
(demography/life style)
Questionnaire
History and chronic medical conditions Questionnaire
Received diagnostics/treatments for MUPS Questionnaire
Outcome measures:
Number/severity of symptoms PHQ-15 [27,28]
Number of symptoms PSQ [63]
Functional impairment RAND36 [31]
Health care use Subscale TIC-P [32]
Depression QIDS-SR [33]
Anxiety BAI [34,35]
Potential predictors:
Perfectionism MDPS [43,44]
Personality (neuroticism, extraversion) Subscales NEO-FFI [41,42]
Cognitions and coping CBRQ [38]
Positive affect Subscale PANAS [64]
Hypervigilance SSAS [36,37]
Illness perception IPQ-K [39,40]
Causal attributions IPQ-K and CBRQ
Depression QIDS-SR [33]
Anxiety BAI [34,35]
Hypochondria WI [45,37]
Life events LEQ [47]
Social support SoS [48]
Physical activity IPAQ [49,50]The sensitivity theory will be covered by the incorporation of ques-
tionnaires about personality (NEO Personality questionnaire— Five Fac-
tor Inventory [41,42]), perfectionism (Multi-dimensional Perfectionism
Scale [43,44]), psychiatric co-morbidity (medical chart, Quick Inventory
of Depressive Symptomatology [33], BeckAnxiety Inventory [34,35] and
Whitely Index for hypochondria [45,37]), positive affect (subscale of
Positive And Negative Affect Schedule [46]), life events (Life Events
Questionnaire [47]), social support (Social Support scale [48]) and phys-
ical activity (International Physical Activity Questionnaire [49,50]).
An overview of all questionnaires and moments of administration is
given in Table 1. Follow-upmeasurements will take place after 6, 12, 24
and 36 months. At baseline and follow-up all relevant questionnaires
will be presented to participants as one instrument (one booklet), for
ease of use. The baseline measurement consists of questionnaires re-
garding a comprehensive set of possible predictors. Only the question-
naires measuring perfectionism and personality will be postponed
until the ﬁrst follow-up measurement (T1), in order to reduce partici-
pant burden at baseline. In adults these factors are considered to be
relatively stable over time [51].
Potential predictors — physiological assessments
The theory of endocrine dysregulation (see Introduction) will be
tested by measurement of free salivary cortisol levels. Salivary cortisol
levels correspond well with cortisol levels in plasma [52]. As solitary
cortisol measurements have low intra-individual stability, in this
study cortisol levels in response to a stressor will be investigated. As a
measure of a natural stress response of the HPA axis, the morning Cor-
tisol Awakening Response (CAR) will be assessed at baseline and after
12 months of follow-up. All patients will collect saliva samples at awak-
ening time (T0), and 30 (T1) and 60 min (T2) afterwards, as it is known
that cortisol levels rise during the ﬁrst 30 min after awakening and re-
main elevated for at least 60 min [53]. They collect saliva at home
using Salivettes® (Sarstedt, Etten-Leur, The Netherlands), according to
the guideline of the manufacturer. Samples will be stored in home re-
frigerators and returned by mail as quick as possible. Returned swabs
will be centrifuged and analyzed [54]. The area under the curve withBaseline
(T0)
6 mo
(T1)
12 mo
(T2)
24 mo
(T3)
36 mo
(T4)
x
x
x x x x x
x x x x x
x
x x x x x
x x x x
x x x
x x x
x
x
x x x x x
x x x x x
x
x x x x x
x x x x x
x x x
x x x
x x x
x
x x x
x x x
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to the increase (AUCi) will be calculated using the formulas described
by Pruessner et al. in 2003 [55]. The AUCg is an estimate of the total cor-
tisol secretion over the ﬁrst hour after awakening, whereas the AUCi is a
measure of its time-dependent change.
Treatments
In this study the natural course of MUPS is investigated, therefore no
speciﬁc treatment is offered to participants. However, during follow-up
patients might be treated by their GP or specialist. As treatmentmay in-
ﬂuence the course of MUPS, we will ask about received treatments at
follow-up. Speciﬁc questions will be asked about treatments performed
by for example the GP, physiotherapists, psychologists, secondary care
somatic specialists or alternative caregivers. Received treatments will
be considered as a covariate in the statistical analysis.
Power calculation
Our sample size calculation is based on the prediction model for the
course of MUPS that we aim to develop. A rule of thumb states that the
number of ‘events’ should be ≥10 for every variable in a multivariate
prediction model [56]. We plan to develop a model with approximately
6 variables. Hence at least 6 × 10 = 60 events will be needed. Possible
‘events’ according to the course ofMUPS are recovery, chronicity and re-
currence (i.e. after a period of absence of symptoms). Of these, chronic-
ity is the most restrictive. According to a Dutch review deterioration of
physical symptoms (and thus chronicity) occurs in 10–30% ofMUPS pa-
tients [21]. As this percentage does not include chronic MUPS patients
with a stable level of physical symptoms, we estimate the incidence of
chronicity to be at least 30%. Therefore we need 200 evaluable patients
to expect 60 events (chronicity) in both primary and secondary care
study groups.
Taking into account an expected loss to follow up of 10%,we aim at a
study sample of 450 patients, divided over the 2 study groups (225 pa-
tients per group). For the other study aims, this number of participants
is more than sufﬁcient.
Statistical analysis
Descriptive statistics (e.g. frequencies and percentages or
mean ± SD) will be used to summarize the demographic characteris-
tics and primary outcomes of the study population in all settings and
at all follow-up moments. Cross-sectional relations between severity
of MUPS and functional impairment or health care use at baseline will
be analyzed, corrected for age, gender and co-morbidity.
Latent Class Growth Mixture Modeling
One of the aims of our study is to identify distinct course types of se-
verity of symptoms, functional outcome and health care use. These out-
come measures are registered at baseline and 4 times during a 3 year
follow-up, leading to 4 estimates of changes in outcomes. As a result,
longitudinal patterns (trajectories) of these outcomes can be evaluated
over time. It is expected that these trajectories vary across participants.
Therefore, Latent Class Growth Mixture Modeling (LCGMM) will be
used to form a smaller amount of distinct clusters (latent trajectory clas-
ses), based on the outcomemeasures [57]. We will use LCGMM instead
of Latent Class Growth Analysis (another modeling method to statisti-
cally derive distinct subgroups) as it allows a certain level of variation
intercept and slope in one or more classes, leading to larger within
class heterogeneity. The optimal number of clusters will be determined
using statistical parameters, including Bayesian Information Criterion
[58] and the bootstrapped likelihood ratio test [59]. Additionally, clinical
interpretation of the clusters will guide the ﬁnal classiﬁcation, in order
to avoid clinically uninterpretable clusters. Patients will be assigned to
speciﬁc clusters based on the posterior probabilities to ﬁt in the cluster,
using Bayesian statistics [60].We will use LCGMM, as it allows us to create subgroups based on
registered characteristics (and change of characteristics). As a result,
identiﬁed subgroups will form a closer approximation of the complex
reality, compared to subgroups based on predeﬁned (subjective)
questionnaire cut offs.
Multivariate prediction model
As a second step, logistic regressionwill be used to identify the com-
binations of risk factors which are associated with the identiﬁed course
types. Depending on the number of subgroups resulting from the latent
class analysis, binary logistic regression or ordinal regression will be
used. In this analysis all baseline characteristics will be taken into ac-
count as potential predictors. Results will be presented as odds ratios
with 95% conﬁdence intervals. The aim is to create one or more multi-
factor prediction models, consisting of approximately 6 determinants
predicting the identiﬁed course types of MUPS. Predictors with a
p ≤ 0.157 will remain in the ﬁnal prediction model(s) [56]. Reliability
of the prediction model will be tested through a calibration plot, in
which the observed frequency of all course types is plotted against the
predicted chance of this course. The discriminating value will be inves-
tigated by calculating the area under the ROC-curve (AUC). Internal
validity of the model will be investigated through a bootstrapping pro-
cedure. Data analysis will be performed with software packages of SPSS
and Mplus. Model assumptions will be checked prior to the analysis.
Bias handling
Selection bias
Hypothetically, the prevalence of severe MUPS may be higher
among non-responders, as patients with severe complaints may not
have the energy to participate. Other groups that may show a lower
response (for the same reason) are the elderly and patientswith psychi-
atric co-morbidity.
To minimize this effect, we will stimulate all eligible patients to
participate, also when they have more severe symptoms. Additionally,
we will ask non-responders a few questions about the reason for not
participating. A non-response analysis will be performed.
Attrition bias
It is conceivable that patients with severe complaints or co-
morbidities may prematurely end study participation, as participation
costs energy, but has no apparent personal advantages. To stimulate
continuation of participation, small incentives (e.g. gift coupons) will
be provided during follow-up. In case of discontinuation, patients will
be stimulated to resume participation. All reasons for discontinuation
will be collected, analyzed and reported. In addition, baseline character-
istics, including severity of symptoms, will be compared between par-
ticipants and drop-outs. In case of missing follow-up data imputation
techniques will be considered.
Discussion
Health care workers in primary care and secondary care are
confrontedwith patients withMUPS on a daily basis.MUPS patients, es-
pecially those with persistent MUPS face various insecurities, as their
symptoms are not (fully) medically explained. Current knowledge
about prognosis is limited and treatment options are scarce. This
study will add to earlier studies, as it will have a long follow-up period.
Additionally, we will register possible treatments, have an additional
focus on functional impairment and identify predictors of the course
of MUPS.
When designing the study, the greatest challenge concerned the
inclusion procedure, especially in primary care. In various previous
studies, selection of MUPS patients was based on searches in GPs' elec-
tronic databases. Unfortunately, a speciﬁc ICPC code forMUPS is lacking.
Therefore, criteria such as the Robbins criteria have often been used as a
205N. van Dessel et al. / Journal of Psychosomatic Research 76 (2014) 200–206proxy to identify possible MUPS cases [3,61]. As Robbins' list symptoms
are not always unexplained, a disadvantage of this method can be the
selection of patients with symptoms that do not ﬁt the criteria for
MUPS (false positives). Furthermore, as selection results depend on
proper registration by GPs, possible MUPS cases might be missed in
case of suboptimal registration of consultations (false negatives).
In other studies questionnaires such as the PHQ-15 have been
used as a screening instrument for possible MUPS patients [62]. The
PHQ-15 is a validated and widely used instrument for this aim, evaluat-
ing 15 symptoms that account formore than 90%of all reportedphysical
symptoms. The PHQ-15 reﬂects the symptoms reported by the patient.
However, the scale only includes a somatic symptom count. Therefore,
an additional evaluation of the nature of the symptoms by a physician
is needed to conﬁrm the existence of MUPS.
In this study, wewill combine bothmethods. A digital search strate-
gy based on the Robbins list will be used as a ﬁrst step. Afterwards, the
selected patients will be screened for in- and exclusion criteria by the
GP. As a third step, selected patients will be asked to ﬁll in the PHQ-15
questionnaire, to objectify the current existence of symptoms. This com-
bination will lead to a ﬁnal selection of ‘true’MUPS patients. This meth-
od has thedisadvantage thatMUPS patientsmay bemissed, for example
due to incorrect registration by GPs or a coincidentally low number of
doctor visits in the last 3 months. Although we do believe that in this
study it is not essential to select all MUPS patients in our population
(as we do not study the prevalence of MUPS), we will try to overcome
this disadvantage as much as possible, as a representative sample is es-
sential. We will do this by selecting GPs with ICPC coding experience,
using relatively low-threshold selection criteria and by the inclusion of
patients in different health care settings.
In secondary care, we will recruit patients in specialized MUPS care
settings. Therefore, it is a limitation to this study that the results in
this study group are not generalizable to the complete population as
seen by somatic specialists in secondary care. Despite the fact that we
do not include patients in these settings, we do believe that the de-
scribed group will not be completely missed. At some point patients
with MUPS who are seen by somatic specialists will be referred back
to their GP (as no diagnosis can be established) or to specialized
MUPS care. As a result, an unknown percentage of these patients will
be included via the included study groups.
The aim of this study is restricted to patient related factors inﬂuenc-
ing the course of MUPS. As a result, other potential inﬂuencing factors,
such as the doctor–patient relationship or communication will not be
taken into account in this study.
We believe that study results will provide extensive information
about course and prognosis. This information can be used directly in
clinical practice, for example in patient education. Additionally, identiﬁ-
cation of predictors of the course of MUPS may lead to better recogni-
tion of patients at risk for persistent symptoms, who may beneﬁt from
treatment. It may also lead to identiﬁcation of relevant treatment
targets.
Taking together all these practical implications, we do believe that
this study has great relevance for clinical practice. We aim to complete
the study in 2016.
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